☆ 4.7 Article

Oncogenic BRAF and p53 Interplay in Melanoma Cells and the Effects of the HDAC Inhibitor ITF2357 (Givinostat)

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Related references

Note: Only part of the references are listed.

Review Biochemistry & Molecular Biology

p53 Family in Resistance to Targeted Therapy of Melanoma

Ignacija Vlasic et al.

Summary: Metastatic melanoma, a highly aggressive tumor, is often characterized by mutations in the MAPK pathway, particularly in the protein kinase BRAF. However, resistance to BRAF inhibitors is a major obstacle in melanoma treatment, with the reactivation of MAPK or PI3K/AKT pathways and the involvement of the p53 pathway contributing to acquired resistance. In melanoma, the canonical tumor suppressor p53 is frequently inactivated through various mechanisms. The TP53 gene and its family members TP63 and TP73 encode multiple protein isoforms with diverse functions in tumorigenesis. Some p53 isoforms are expressed in melanoma cells and have been shown to play specific roles in proliferation, survival, metastasis, invasion, migration, and treatment response. Particularly, p53 isoforms involved in acquired resistance to MAPK inhibitors present potential therapeutic targets to overcome resistance in melanoma.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Targeting Y220C mutated p53 by Foeniculum vulgare-derived phytochemicals as cancer therapeutics

Saksham Garg et al.

Summary: Mutations in the TP53 gene are common in cancer cells and disrupt the function of p53, allowing tumor growth. Targeting mutant p53 to restore its tumor suppression activity is a potential cancer therapy. This study explored the therapeutic potential of small phytochemicals from Foeniculum vulgare to reactivate mutant p53 (Y220C) through molecular docking simulation. The results showed that juglalin, retinol, and 3-nitrofluoranthene could bind to the mutated site and may be used for drug design against Y220C mutant p53.

JOURNAL OF MOLECULAR MODELING (2023)

Add to Collection

Article Oncology

Effects of BRAF V600E and NRAS mutational status on the progression-free survival and clinicopathological characteristics of patients with melanoma

Tatjana Zablocka et al.

Summary: Hotspot mutations of the BRAF and NRAS genes are common in invasive cutaneous melanoma, but the prognostic significance of their co-mutations is controversial. This study aimed to determine the association between NRAS and BRAF mutation status and clinicopathological characteristics in melanoma patients. The results showed that NRAS and BRAF co-mutations were associated with worse progression-free survival (PFS), and NRAS mutation status was related to tumor thickness, type, mitotic rate, and lymphovascular invasion. The assessment of NRAS mutation status may be beneficial for risk stratification in primary non-metastatic malignant melanoma.

ONCOLOGY LETTERS (2023)

Add to Collection

Article Cell Biology

Targeting KRAS-mutant stomach/colorectal tumors by disrupting the ERK2-p53 complex

Xiang Wang et al.

Cell Reports (2023)

Add to Collection

Article Oncology

F-Box Protein 43, Stabilized by N6-Methyladenosine Methylation, Enhances Hepatocellular Carcinoma Cell Growth and Invasion via Promoting p53 Degradation in a Ubiquitin Conjugating Enzyme E2 C-Dependent Manner

Huijun Zhou et al.

Summary: This study investigated the expression, clinical significance, and mechanisms of FBXO43 in hepatocellular carcinoma (HCC). The upregulation of FBXO43 in HCC was associated with advanced progression and poor prognosis. It was found that METTL3 and IGF2BP2 mediated the m6A modification of FBXO43, contributing to its stabilization and upregulation in HCC. Furthermore, FBXO43 promoted HCC progression by inducing p53 degradation through UBE2C upregulation.

CANCERS (2023)

Add to Collection

Review Oncology

Drugs Targeting p53 Mutations with FDA Approval and in Clinical Trials

Shigeto Nishikawa et al.

Summary: Mutations in the tumor suppressor p53 occur in about 50% of human cancers, leading to impaired tumor suppressive function and oncogenic activities of mutant p53. Various approaches, including restoration of wild-type p53 conformation, rescue of p53 nonsense mutations, depletion of mutant p53 proteins, and induction of p53 synthetic lethality or targeting of vulnerabilities imposed by p53 mutations, have been used to target p53 mutations in the development of cancer therapies. This review article summarizes the mechanisms of action and activities of clinically available FDA-approved drugs and drugs in clinical trials that target p53 mutations for suppressing cancer progression.

CANCERS (2023)

Add to Collection

Article Oncology

YO2 Induces Melanoma Cell Apoptosis through p53-Mediated LRP1 Downregulation

Yousef Salama et al.

Summary: We discovered that induction of tumor suppressor p53 in melanoma cells inhibits tumor growth by targeting LRP1 expression, which is achieved through microRNAs miR103/107. We identified the small molecule YO-2 as an inducer of p53 and proposed its combination with doxorubicin as a novel treatment option. These findings highlight the importance of p53 and LRP1 in melanoma growth and suggest potential therapeutic strategies.

CANCERS (2023)

Add to Collection

Letter Oncology

Selective degradation of the p53-R175H oncogenic hotspot mutant by an RNA aptamer-based PROTAC

Lingping Kong et al.

CLINICAL AND TRANSLATIONAL MEDICINE (2023)

Add to Collection

Article Medicine, Research & Experimental

HDAC inhibitor ITF2357 reduces resistance of mutant-KRAS non-small cell lung cancer to pemetrexed through a HDAC2/miR-130a-3p-dependent mechanism

Jian Cui et al.

Summary: The HDAC inhibitor ITF2357 restores miR-130a-3p expression by inhibiting HDAC2, thereby repressing Rad51 and ultimately diminishing the resistance of mutant KRAS NSCLC to pemetrexed.

JOURNAL OF TRANSLATIONAL MEDICINE (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Anti-proliferative, pro-apototic and anti-migratory properties of HDAC inhibitor PXD-101 on osteosarcoma cell lines

Michela Rossi et al.

Summary: The effects of the histone deacetylase inhibitor PXD-101 on human osteosarcoma cells were investigated. The study found that PXD-101 inhibited cell proliferation, induced apoptosis, and inhibited cell migration. This study suggests that PXD-101 may be a potential new therapeutic approach for osteosarcoma patients.

ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2023)

Add to Collection

Article Biochemistry & Molecular Biology

p53 partial loss-of-function mutations sensitize to chemotherapy

Boris Klimovich et al.

Summary: Partial loss-of-function mutations of p53 play a significant role in tumorigenesis, leading to mutant p53 protein accumulation similar to hotspot mutations. Unlike p53 loss, these mutations enhance apoptotic chemotherapy response and improve survival rates in a therapy context.

ONCOGENE (2022)

Add to Collection

Article Oncology

A B-Raf V600E gene signature for melanoma predicts prognosis and reveals sensitivity to targeted therapies

Kevin Yao et al.

Summary: In this study, a B-Raf signature score was defined using RNA-seq data, which could predict B-Raf mutation status and other aberrations. Patients dichotomized by the median B-Raf score showed more significant stratification compared to other metrics. High B-Raf score also predicted higher sensitivity to B-Raf inhibitors and drugs targeting other relevant oncogenic pathways.

CANCER MEDICINE (2022)

Add to Collection

Article Cell Biology

p53 Promotes Cytokine Expression in Melanoma to Regulate Drug Resistance and Migration

Pinakin Pandya et al.

Summary: The transcription factor p53 plays an important regulatory role in melanoma, with its loss resulting in reduced cytokine expression, impaired migration ability of tumor and immune cells, and increased sensitivity to BRAF inhibitors.

CELLS (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Localized Proteasomal Degradation: From the Nucleus to Cell Periphery

Xing Guo

Summary: This article summarizes recent advances in the functions, regulations, and targeting mechanisms of proteasomes, particularly those localized in subcellular compartments, and discusses their biological significance in mediating compartmentalized protein degradation.

BIOMOLECULES (2022)

Add to Collection

Article Oncology

Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study

Stergios J. Moschos et al.

Summary: Combining AMG 232, a drug targeting the MDM2-p53 interaction, with MAPK inhibitors showed better safety and efficacy compared to using MAPK inhibitors alone in preclinical melanoma models. However, adding AMG 232 did not provide additional clinical benefit in patients with TP53-wild type, MAPKi-naive metastatic melanoma.

INVESTIGATIONAL NEW DRUGS (2022)

Add to Collection

Article Chemistry, Inorganic & Nuclear

Bortezomib potentiates the antitumor effect of tributyltin(IV) ferulate in colon cancer cells exacerbating ER stress and promoting apoptosis

Adriana Celesia et al.

Summary: Organotin(IV) complexes are potential drugs for cancer therapy. We have reported a new organotin(IV) complex, tributyltin(IV) ferulate (TBT-F), which exhibits antitumor activity in colon cancer cells. In this study, we show that the effectiveness of TBT-F is greatly enhanced when combined with the proteasome inhibitor bortezomib (BTZ). The combination of the two compounds leads to a significant reduction in colon cancer cell viability, disruption of cell morphology, and exacerbation of endoplasmic reticulum stress. This stress promotes apoptosis through the unfolded protein response pathway.

INORGANICA CHIMICA ACTA (2022)

Add to Collection

Review Biochemistry & Molecular Biology

The Role of HDACs in the Response of Cancer Cells to Cellular Stress and the Potential for Therapeutic Intervention

Rahma K. Alseksek et al.

Summary: This article provides an overview of the role of histone deacetylases (HDACs) in cancer cells' adaptive responses to various stress conditions. It discusses the impact of HDACs in regulating cellular systems and evading death pathways, as well as their potential as therapeutic targets. The article also highlights the use of HDAC inhibitors in combination with stress-inducing agents to manage cancer and overcome resistance to current therapies.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection

Article Oncology

Givinostat-Liposomes: Anti-Tumor Effect on 2D and 3D Glioblastoma Models and Pharmacokinetics

Lorenzo Taiarol et al.

Summary: This study demonstrates the anti-tumor activity of the pan-HDAC inhibitor Givinostat and a suitable liposomal formulation. The liposome-Givinostat formulation improves the drug's half-life and brain delivery in a mouse model. Additionally, this formulation shows anti-tumor activity in in vitro models.

CANCERS (2022)

Add to Collection

Article Biochemistry & Molecular Biology

The Histone Deacetylase Inhibitor ITF2357 (Givinostat) Targets Oncogenic BRAF in Melanoma Cells and Promotes a Switch from Pro-Survival Autophagy to Apoptosis

Adriana Celesia et al.

Summary: This study compared the effects of two HDAC inhibitors, ITF2357 and SAHA, in melanoma cells with the BRAF V600E oncogenic mutation. Results showed that ITF2357 was more effective than SAHA in reducing the viability of BRAF-mutated melanoma cells, and it also decreased the expression of oncogenic BRAF protein and induced a switch from autophagy to classic apoptosis.

BIOMEDICINES (2022)

Add to Collection

Article Oncology

Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program

Alessandro Rambaldi et al.

Summary: Givinostat has shown long-term efficacy and safety in patients with PV, with a high overall response rate and low rate of Grade 3 treatment-related adverse events. This supports the long-term use of givinostat in this population.

BLOOD CANCER JOURNAL (2021)

Add to Collection

Review Cell Biology

New Insights into the Link between Melanoma and Thyroid Cancer: Role of Nucleocytoplasmic Trafficking

Mourad Zerfaoui et al.

Summary: The link between melanoma and thyroid cancer may be due to specific gene mutations leading to tumor aggressiveness. Studies indicate an increased mutual risk between melanoma patients and thyroid cancer patients compared to healthy individuals.

CELLS (2021)

Add to Collection

Article Oncology

Altered Expression of Shorter p53 Family Isoforms Can Impact Melanoma Aggressiveness

Ana Tadijan et al.

Summary: The study found that melanoma cells express a wide array of p53 and p73 isoforms, with &UDelta;160p53a showing the most variability. It was demonstrated for the first time that &UDelta;160p53a can be recruited on chromatin and stimulate proliferation and migration. Vemurafenib-resistant melanoma cells exhibited increased expression of potentially pro-oncogenic isoforms and decreased expression of tumor-suppressive isoforms, suggesting a role of p53 family isoforms in melanoma aggressiveness.

CANCERS (2021)

Add to Collection

Article Oncology

Targeting p53 for Melanoma Treatment: Counteracting Tumour Proliferation, Dissemination and Therapeutic Resistance

Joana B. Loureiro et al.

Summary: Melanoma, a deadly form of skin cancer, is highly metastatic and therapy-resistant. The p53-activating agent SLMP53-2 shows promising antitumor activity by inducing cell cycle arrest and apoptosis, inhibiting invasion and migration, and increasing sensitivity to chemotherapy. It also has the potential to improve outcomes in advanced melanoma, either alone or in combination therapy.

CANCERS (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Tributyltin(IV) Butyrate: A Novel Epigenetic Modifier with ER Stress- and Apoptosis-Inducing Properties in Colon Cancer Cells

Michela Giuliano et al.

Summary: Organotin(IV) compounds are a class of non-platinum metallo-conjugates with antitumor properties. Among them, triorganotin(IV) butyrate (BT2) shows high efficacy in colon cancer cells by inducing G2/M cell cycle arrest, ER stress, and apoptotic cell death. Furthermore, BT2 can decrease histone acetylation levels and prevent acetylation induced by other HDAC inhibitors, suggesting its potential as an epigenetic modulator in colon cancer treatment.

MOLECULES (2021)

Add to Collection

Review Endocrinology & Metabolism

Metabolic functions of the tumor suppressor p53: Implications in normal physiology, metabolic disorders, and cancer

Matthieu Lacroix et al.

MOLECULAR METABOLISM (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Paradoxical Role for Wild-Type p53 in Driving Therapy Resistance in Melanoma

Marie R. Webster et al.

MOLECULAR CELL (2020)

Add to Collection

Review Biochemistry & Molecular Biology

The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape

Irene Vanni et al.

FRONTIERS IN MOLECULAR BIOSCIENCES (2020)

Add to Collection

Review Cell Biology

Gain-of-function mutant p53 in cancer progression and therapy

Cen Zhang et al.

JOURNAL OF MOLECULAR CELL BIOLOGY (2020)

Add to Collection

Article Biochemistry & Molecular Biology

ROS-Dependent ER Stress and Autophagy Mediate the Anti-Tumor Effects of Tributyltin (IV) Ferulate in Colon Cancer Cells

Adriana Celesia et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

Add to Collection

Review Oncology

Mutant p53 in Cancer Progression and Targeted Therapies

Gaoyang Zhu et al.

FRONTIERS IN ONCOLOGY (2020)

Add to Collection

Review Biochemistry & Molecular Biology

p53 at the Crossroads between Different Types of HDAC Inhibitor-Mediated Cancer Cell Death

Maria Mrakovcic et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)

Add to Collection

Article Cell Biology

Restoration of p53 acetylation by HDAC inhibition permits the necrosis/apoptosis switch of pancreatic ainar cell during experimental pancreatitis in mice

Yangyang Hu et al.

JOURNAL OF CELLULAR PHYSIOLOGY (2019)

Add to Collection

Article Biotechnology & Applied Microbiology

Histone deacetylase 6 is overexpressed and promotes tumor growth of colon cancer through regulation of the MAPK/ERK signal pathway

Shi-Lan Zhang et al.

ONCOTARGETS AND THERAPY (2019)

Add to Collection

Article Oncology

Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma

Francesco Marampon et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)

Add to Collection

Review Biochemistry & Molecular Biology

Do Mutations Turn p53 into an Oncogene?

Consuelo Pitolli et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)

Add to Collection

Article Oncology

HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma

Stuart J. Gallagher et al.

INTERNATIONAL JOURNAL OF CANCER (2018)

Add to Collection

Article Surgery

Prognostic Role of BRAFV600E Cellular Localization in Melanoma

Zakaria Y. Abd Elmageed et al.

JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2018)

Add to Collection

Article Toxicology

Anticancer potential of benzothiazolic derivative (E)-2-((2-(benzo[d]thiazol-2-yl)hydrazono)methyl)-4-nitrophenol against melanoma cells

Zanair Soares Vasconcelos et al.

TOXICOLOGY IN VITRO (2018)

Add to Collection

Article Nutrition & Dietetics

Sicilian Litchi Fruit Extracts Induce Autophagy versus Apoptosis Switch in Human Colon Cancer Cells

Sonia Emanuele et al.

NUTRIENTS (2018)

Add to Collection

Review Gastroenterology & Hepatology

Histone deacetylases function as novel potential therapeutic targets for cancer

Hui Zhang et al.

HEPATOLOGY RESEARCH (2017)

Add to Collection

Article Oncology

ACY-1215 accelerates vemurafenib induced cell death of BRAF-mutant melanoma cells via induction of ER stress and inhibition of ERK activation

Ueihuei Peng et al.

ONCOLOGY REPORTS (2017)

Add to Collection

Article Oncology

The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL

A. M. Savino et al.

LEUKEMIA (2017)

Add to Collection

Article Cell Biology

Histone deacetylase 3 overexpression in human cholangiocarcinoma and promotion of cell growth via apoptosis inhibition

Yuyao Yin et al.

CELL DEATH & DISEASE (2017)

Add to Collection

Review Biochemistry & Molecular Biology

Putting p53 in Context

Edward R. Kastenhuber et al.

CELL (2017)

Add to Collection

Article Oncology

BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival

Emilia Hugdahl et al.

BRITISH JOURNAL OF CANCER (2016)

Add to Collection

Article Biochemistry & Molecular Biology

Histone Deacetylase Inhibitor Trichostatin a Promotes the Apoptosis of Osteosarcoma Cells through p53 Signaling Pathway Activation

Zhantao Deng et al.

INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2016)

Add to Collection

Article Oncology

Histone deacetylase inhibitor-induced cell death in bladder cancer is associated with chromatin modification and modifying protein expression: A proteomic approach

Qingdi Quentin Li et al.

INTERNATIONAL JOURNAL OF ONCOLOGY (2016)

Add to Collection

Review Oncology

Histone deacetylase inhibitor givinostat: the small-molecule with promising activity against therapeutically challenging haematological malignancies

Shabir Ahmad Ganai

JOURNAL OF CHEMOTHERAPY (2016)

Add to Collection

Article Medicine, Research & Experimental

A novel class I histone deacetylase inhibitor, I-7ab, induces apoptosis and arrests cell cycle progression in human colorectal cancer cells

Liyan Yang et al.

BIOMEDICINE & PHARMACOTHERAPY (2015)

Add to Collection

Article Multidisciplinary Sciences

Survival According to BRAF-V600 Tumor Mutations - An Analysis of 437 Patients with Primary Melanoma

Diana Meckbach et al.

PLOS ONE (2014)

Add to Collection

Article Endocrinology & Metabolism

BAG3 Down-Modulation Reduces Anaplastic Thyroid Tumor Growth by Enhancing Proteasome-Mediated Degradation of BRAF Protein

Gennaro Chiappetta et al.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)

Add to Collection

Article Oncology

P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation

Kelly A. Avery-Kiejda et al.

BMC CANCER (2011)

Add to Collection

Article Oncology

Clinical Correlates of NRAS and BRAF Mutations in Primary Human Melanoma

Julie A. Ellerhorst et al.

CLINICAL CANCER RESEARCH (2011)

Add to Collection

Article Oncology

Mutation analysis of 24 known cancer genes in the NCI-60 cell line set

Ogechi N. Ikediobi et al.

MOLECULAR CANCER THERAPEUTICS (2006)

Add to Collection

Article Biochemistry & Molecular Biology

BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma

EE Patton et al.

CURRENT BIOLOGY (2005)

Add to Collection

Article Oncology

Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas

M Shinozaki et al.

CLINICAL CANCER RESEARCH (2004)

Add to Collection

Letter Biochemistry & Molecular Biology

Induction of apoptosis in human osteosarcoma Saos-2 cells by the proteasome inhibitor MG132 and the protective effect of pRb

M Lauricella et al.

CELL DEATH AND DIFFERENTIATION (2003)

Add to Collection

© Peeref 2019-2024. All rights reserved.